About Pulmonx
Pulmonx is a company based in Redwood City (United States) founded in 1998. Pulmonx has raised $280.91 million across 15 funding rounds from investors including Canadian Imperial Bank of Commerce, Kleiner Perkins and RTW Investments. The company has 291 employees as of December 31, 2024. Pulmonx has completed 2 acquisitions, including Aeris Therapeutics and Emphasys Medical. Pulmonx offers products and services including Zephyr Valves, Chartis System, and StratX Reports. Pulmonx operates in a competitive market with competitors including Neurent Medical, Gradient Denervation Technologies, Spiration, Uptake Medical and Emphasys Medical, among others.
- Headquarter Redwood City, United States
- Employees 291 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pulmonx Corporation
-
Annual Revenue
$83.79 M (USD)22.01as on Dec 31, 2024
-
Net Profit
-$56.39 M (USD)7.31as on Dec 31, 2024
-
EBITDA
-$54.39 M (USD)9.32as on Dec 31, 2024
-
Total Equity Funding
$280.91 M (USD)
in 15 rounds
-
Latest Funding Round
$66 M (USD), Series D
May 05, 2020
-
Investors
Canadian Imperial Bank of Commerce
& 15 more
-
Employee Count
291
as on Dec 31, 2024
-
Investments & Acquisitions
Aeris Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pulmonx
Pulmonx is a publicly listed company on the NASDAQ with ticker symbol LUNG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pulmonx
Pulmonx offers a comprehensive portfolio of products and services, including Zephyr Valves, Chartis System, and StratX Reports.
Device for treating severe COPD by reducing hyperinflation.
System for assessing patients' pulmonary function.
Reports for evaluating CT scans in COPD treatment.
People of Pulmonx
Unlock access to complete
Unlock access to complete
Software Development Team
30 people
Leadership Team
23 people
Sales and Marketing
19 people
Finance and Accounting
8 people
Legal and Compliance
5 people
Operations Team
3 people
Senior Team
3 people
Human Resources and Administration
3 people
Unlock access to complete
Funding Insights of Pulmonx
Pulmonx has successfully raised a total of $280.91M across 15 strategic funding rounds. The most recent funding activity was a Series D round of $66 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pulmonx
Pulmonx has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Canadian Imperial Bank of Commerce, Kleiner Perkins and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on tech and life sciences startups.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked |
Investor details for Pulmonx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pulmonx
Pulmonx has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aeris Therapeutics and Emphasys Medical.
Investment portfolio details for Pulmonx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Products for treating emphysema and lung diseases are developed.
|
Locked | Locked | 2000 | Locked | |
|
Endobronchial valves for emphysema treatment are developed.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Pulmonx
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Pulmonx
Detailed financials for Pulmonx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pulmonx Comparisons
Peer comparison for Pulmonx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pulmonx
Pulmonx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurent Medical, Gradient Denervation Technologies, Spiration, Uptake Medical and Emphasys Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Smart devices for minimally invasive rhinitis treatment are developed.
|
|
| Locked | Locked | Locked |
Endovascular catheter-based technology for pulmonary hypertension treatment is provided.
|
|
| Locked | Locked | Locked |
IntraBronchial Valve to treat lung disease
|
|
| Locked | Locked | Locked |
Targeted vapor therapy is developed for endoscopic lung volume reduction.
|
|
| Locked | Locked | Locked |
Endobronchial valves for emphysema treatment are developed.
|
Detailed competitors of Pulmonx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pulmonx
Complete news archive for Pulmonx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pulmonx
Pulmonx was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Pulmonx is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Glen French is the current CEO of Pulmonx.
Pulmonx is a funded company, having raised a total of $280.91M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Pulmonx is 291.
Annual revenue of Pulmonx is $83.79M as on Dec 31, 2024.
Pulmonx is a developer of smart devices for treating pulmonary diseases. The company is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. It is currently engaged in the design, development, and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The companys Zephyr Endobronchial Valve (EBV) therapy involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The company has a CE Mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System.
Pulmonx's top competitors include Neurent Medical, Gradient Denervation Technologies and Spiration.
Pulmonx offers Zephyr Valves, Chartis System, and StratX Reports.
Yes, Pulmonx is publicly traded on NASDAQ under the ticker symbol LUNG.
Pulmonx has made 2 acquisitions, including Aeris Therapeutics, and Emphasys Medical.
Pulmonx has 16 investors. Key investors include Canadian Imperial Bank of Commerce, Kleiner Perkins, RTW Investments, Driehaus, and Oxford Finance.
The ticker symbol of Pulmonx is LUNG on NASDAQ.